Article

Novel ICL: Low adverse events in highly myopic special-needs children

Author(s):

The rate of adverse events was low in this higher risk, difficult-to-manage population of special-needs children, noted Margaret Reynolds, MD.

 highly myopic special-needs children

The most common adverse event was pupillary block due to closure of the iridotomy.

Margaret Reynolds, MD, and colleagues from the St. Louis Children's Hospital at Washington University Medical Center, St. Louis, conducted a study to evaluate the safety of the Visian Intraocular Collamer Lens (ICL) (Staar Surgical) in highly myopic special-needs pediatric cases. The most common adverse event was pupillary block due to closure of the iridotomy.

This retrospective case series1 included 95 special-needs children (160 eyes) with high ametropia who had been implanted with the Visian ICL over the previous 5 years. The surgeries were performed with the children under general anesthesia.

The children were followed for a mean follow-up period of 2.0 ± 1.4 years (range, 0.5-5.2) to determine the safety of the lens in this patient population. The investigators collected the rates and case specifics of perioperative and longer term adverse events.

ICL results

The patients were a mean age of 9.3 ± 5.2 years (range, 1.8-25) at the time the lens was implanted. The mean preoperative spherical equivalent refractive error was −11.20 ± 3.90 diopters (range, 4-22). Of the 95 children, 62 children (65%) had a neurodevelopmental disorder.

A minor adverse event was ocular hypertension in response to steroids that occurred in 3 eyes (2%) and resolved when the steroids were stopped.

The most frequently occurring major adverse event was postoperative pupillary block that required revision of the peripheral iridotomy in 7 eyes (4%).

Other adverse events that developed in 1 eye each (0.6%) included a wound leak in a 1 child who was self-injurious and required repair; a cataract in 1 child with Down syndrome 2.8 years after the ICL surgery, and a traumatic retinal detachment in 1 child with severe autism spectrum disorder 1.2 years after the ICL implantation.

The endothelial cell loss over the follow-up period averaged 8.1%, which was comparable to that in adults implanted with the ICL.

Reynolds commented, “The rate of adverse events was low in this higher risk, difficult-to-manage population of special-needs children.”

Reference
  1. Reynolds M, Hoekel H, Tychsen L. Safety of phakic intraocular collamer lens implantation in 95 highly myopic special-needs children. J Cataract Refract Surg. 2021;47:1519-1523; doi: 10.1097/j.jcrs.0000000000000678

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
© 2025 MJH Life Sciences

All rights reserved.